Last reviewed · How we verify
Norprolac
Norprolac is a Small molecule drug developed by Ferring Pharmaceuticals. It is currently in Phase 2 development.
Norprolac, also known as Quinagolide, is a selective dopamine D2 receptor agonist used to manage hyperprolactinemia. It is also effective in treating breast pain and is available in the UK, but not in the US.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Norprolac |
|---|---|
| Sponsor | Ferring Pharmaceuticals |
| Target | Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain (PHASE2)
- Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis (PHASE2)
- PRolaCT - Three Prolactinoma RCTs (PHASE4)
- Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide (PHASE2)
- Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome (PHASE2)
- Endometriosis Patients Undergoing Quinagolide Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norprolac CI brief — competitive landscape report
- Norprolac updates RSS · CI watch RSS
- Ferring Pharmaceuticals portfolio CI
Frequently asked questions about Norprolac
What is Norprolac?
Who makes Norprolac?
What development phase is Norprolac in?
What does Norprolac target?
Related
- Target: All drugs targeting Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, Dopamine receptor
- Manufacturer: Ferring Pharmaceuticals — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing